Holmium laser enucleation of the prostate and perioperative diagnosis of prostate cancer: An outcomes analysis

Marcelino E. Rivera, Igor Frank, Boyd R. Viers, Laureano J. Rangel, Amy Krambeck

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: Our objective is to assess the outcomes of patients with prostate cancer (PCa) diagnoses undergoing holmium laser enucleation of the prostate (HoLEP). Methods: From 2009 to 2012, 450 patients underwent HoLEP at our institution. We performed a retrospective review of these patients to identify those with PCa. Results: PCa was diagnosed in 57 (12.7%) HoLEP patients: 11 (19.2%) preoperatively, 43 (75.4%) in the operative specimen, and 3 (5.4%) during follow-up. Mean time to PCa development in the postoperative group was 16 months (9-23). There was no difference in patient characteristics for those diagnosed with PCa at the time of HoLEP or in the postoperative period. There were 5 patients with a Gleason score (GS)>8 and 52 with GS<8 PCa. In the operative group, 39 (91%) elected for active surveillance and 4 (9%) elected to have cancer treatment. In subgroup analysis, men diagnosed with GS>8 intraoperatively or postoperatively had significantly elevated preoperative, postoperative, and percent change prostate-specific antigen (PSA) levels when compared to patients diagnosed GS≤7 (P=0.01, 0.02, and 0.01, respectively). There were no complications, all voided spontaneously, and one patient had persistent incontinence. Conclusion: HoLEP for the treatment of lower urinary tract symptoms (LUTS) in selectively chosen men with known PCa can safely improve urination. Furthermore, PCa is diagnosed at the time of or post HoLEP in nearly 12% of patients. Those patients with persistently elevated post HoLEP PSA levels or low percent change PSA levels should raise suspicion for high GS PCa. Finally, HoLEP does not preclude active surveillance or treatment for PCa when appropriate.

Original languageEnglish (US)
Pages (from-to)699-703
Number of pages5
JournalJournal of Endourology
Volume28
Issue number6
DOIs
StatePublished - Jun 1 2014
Externally publishedYes

Fingerprint

Solid-State Lasers
Prostate
Prostatic Neoplasms
Prostate-Specific Antigen
Neoplasm Grading
Lower Urinary Tract Symptoms
Urination
Postoperative Period

ASJC Scopus subject areas

  • Urology

Cite this

Holmium laser enucleation of the prostate and perioperative diagnosis of prostate cancer : An outcomes analysis. / Rivera, Marcelino E.; Frank, Igor; Viers, Boyd R.; Rangel, Laureano J.; Krambeck, Amy.

In: Journal of Endourology, Vol. 28, No. 6, 01.06.2014, p. 699-703.

Research output: Contribution to journalArticle

Rivera, Marcelino E. ; Frank, Igor ; Viers, Boyd R. ; Rangel, Laureano J. ; Krambeck, Amy. / Holmium laser enucleation of the prostate and perioperative diagnosis of prostate cancer : An outcomes analysis. In: Journal of Endourology. 2014 ; Vol. 28, No. 6. pp. 699-703.
@article{5062f3888a1640d4903ffd74a4163311,
title = "Holmium laser enucleation of the prostate and perioperative diagnosis of prostate cancer: An outcomes analysis",
abstract = "Objective: Our objective is to assess the outcomes of patients with prostate cancer (PCa) diagnoses undergoing holmium laser enucleation of the prostate (HoLEP). Methods: From 2009 to 2012, 450 patients underwent HoLEP at our institution. We performed a retrospective review of these patients to identify those with PCa. Results: PCa was diagnosed in 57 (12.7{\%}) HoLEP patients: 11 (19.2{\%}) preoperatively, 43 (75.4{\%}) in the operative specimen, and 3 (5.4{\%}) during follow-up. Mean time to PCa development in the postoperative group was 16 months (9-23). There was no difference in patient characteristics for those diagnosed with PCa at the time of HoLEP or in the postoperative period. There were 5 patients with a Gleason score (GS)>8 and 52 with GS<8 PCa. In the operative group, 39 (91{\%}) elected for active surveillance and 4 (9{\%}) elected to have cancer treatment. In subgroup analysis, men diagnosed with GS>8 intraoperatively or postoperatively had significantly elevated preoperative, postoperative, and percent change prostate-specific antigen (PSA) levels when compared to patients diagnosed GS≤7 (P=0.01, 0.02, and 0.01, respectively). There were no complications, all voided spontaneously, and one patient had persistent incontinence. Conclusion: HoLEP for the treatment of lower urinary tract symptoms (LUTS) in selectively chosen men with known PCa can safely improve urination. Furthermore, PCa is diagnosed at the time of or post HoLEP in nearly 12{\%} of patients. Those patients with persistently elevated post HoLEP PSA levels or low percent change PSA levels should raise suspicion for high GS PCa. Finally, HoLEP does not preclude active surveillance or treatment for PCa when appropriate.",
author = "Rivera, {Marcelino E.} and Igor Frank and Viers, {Boyd R.} and Rangel, {Laureano J.} and Amy Krambeck",
year = "2014",
month = "6",
day = "1",
doi = "10.1089/end.2014.0009",
language = "English (US)",
volume = "28",
pages = "699--703",
journal = "Journal of Endourology",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Holmium laser enucleation of the prostate and perioperative diagnosis of prostate cancer

T2 - An outcomes analysis

AU - Rivera, Marcelino E.

AU - Frank, Igor

AU - Viers, Boyd R.

AU - Rangel, Laureano J.

AU - Krambeck, Amy

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Objective: Our objective is to assess the outcomes of patients with prostate cancer (PCa) diagnoses undergoing holmium laser enucleation of the prostate (HoLEP). Methods: From 2009 to 2012, 450 patients underwent HoLEP at our institution. We performed a retrospective review of these patients to identify those with PCa. Results: PCa was diagnosed in 57 (12.7%) HoLEP patients: 11 (19.2%) preoperatively, 43 (75.4%) in the operative specimen, and 3 (5.4%) during follow-up. Mean time to PCa development in the postoperative group was 16 months (9-23). There was no difference in patient characteristics for those diagnosed with PCa at the time of HoLEP or in the postoperative period. There were 5 patients with a Gleason score (GS)>8 and 52 with GS<8 PCa. In the operative group, 39 (91%) elected for active surveillance and 4 (9%) elected to have cancer treatment. In subgroup analysis, men diagnosed with GS>8 intraoperatively or postoperatively had significantly elevated preoperative, postoperative, and percent change prostate-specific antigen (PSA) levels when compared to patients diagnosed GS≤7 (P=0.01, 0.02, and 0.01, respectively). There were no complications, all voided spontaneously, and one patient had persistent incontinence. Conclusion: HoLEP for the treatment of lower urinary tract symptoms (LUTS) in selectively chosen men with known PCa can safely improve urination. Furthermore, PCa is diagnosed at the time of or post HoLEP in nearly 12% of patients. Those patients with persistently elevated post HoLEP PSA levels or low percent change PSA levels should raise suspicion for high GS PCa. Finally, HoLEP does not preclude active surveillance or treatment for PCa when appropriate.

AB - Objective: Our objective is to assess the outcomes of patients with prostate cancer (PCa) diagnoses undergoing holmium laser enucleation of the prostate (HoLEP). Methods: From 2009 to 2012, 450 patients underwent HoLEP at our institution. We performed a retrospective review of these patients to identify those with PCa. Results: PCa was diagnosed in 57 (12.7%) HoLEP patients: 11 (19.2%) preoperatively, 43 (75.4%) in the operative specimen, and 3 (5.4%) during follow-up. Mean time to PCa development in the postoperative group was 16 months (9-23). There was no difference in patient characteristics for those diagnosed with PCa at the time of HoLEP or in the postoperative period. There were 5 patients with a Gleason score (GS)>8 and 52 with GS<8 PCa. In the operative group, 39 (91%) elected for active surveillance and 4 (9%) elected to have cancer treatment. In subgroup analysis, men diagnosed with GS>8 intraoperatively or postoperatively had significantly elevated preoperative, postoperative, and percent change prostate-specific antigen (PSA) levels when compared to patients diagnosed GS≤7 (P=0.01, 0.02, and 0.01, respectively). There were no complications, all voided spontaneously, and one patient had persistent incontinence. Conclusion: HoLEP for the treatment of lower urinary tract symptoms (LUTS) in selectively chosen men with known PCa can safely improve urination. Furthermore, PCa is diagnosed at the time of or post HoLEP in nearly 12% of patients. Those patients with persistently elevated post HoLEP PSA levels or low percent change PSA levels should raise suspicion for high GS PCa. Finally, HoLEP does not preclude active surveillance or treatment for PCa when appropriate.

UR - http://www.scopus.com/inward/record.url?scp=84901987163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901987163&partnerID=8YFLogxK

U2 - 10.1089/end.2014.0009

DO - 10.1089/end.2014.0009

M3 - Article

C2 - 24484284

AN - SCOPUS:84901987163

VL - 28

SP - 699

EP - 703

JO - Journal of Endourology

JF - Journal of Endourology

SN - 0892-7790

IS - 6

ER -